| Date:               | 2022/11/30            |  |
|---------------------|-----------------------|--|
| Your Name:          | Lubiao Liang_         |  |
| Manuscript Title:_D | iagnosis and treatmer | nt of pericardial mesothelioma by mediastinal mass resection: A case |
| report              |                       |  |
| Manuscript number   | (if known):           |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | T                             | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations,                | XNone  |  |
|----|--|--------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6  | Payment for expert testimony                                     | XNone  |  |
| 7  | Support for attending meetings and/or travel                     | XNone  |  |
|    |  |        |  |
| 8  | Patents planned, issued or pending                               | XNone  |  |
| 9  | Participation on a Data  | X None |  |
| -  | Safety Monitoring Board or                                       |        |  |
| 10 | Advisory Board<br>Leadership or fiduciary role                   | X None |  |
| 10 | in other board, society,   |        |  |
|    | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11 | Stock or stock options   | XNone  |  |
|    |  |        |  |
| 12 | Receipt of equipment,  | X None |  |
| 12 | materials, drugs, medical  |        |  |
|    | writing, gifts or other<br>services                              |        |  |
| 13 | Other financial or non-  | XNone  |  |
|    | financial interests  |        |  |
|    |  |        |  |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date:      | 2022/11/30                   |   |
|------------|------------------------------|---|
| Your Name: | Xiao Zhang                   |   |
| Manuscript | Title:_Diagnosis and treatme | ent of pericardial mesothelioma by mediastinal mass resection: A case |
| report     | _                            |   |
| Manuscript | number (if known):           |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | r                             | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| Payment or honoraria for lectures, presentations,                | XNone  |   |
|--|--|---|
| speakers bureaus,<br>manuscript writing or<br>educational events |  |   |
| Payment for expert testimony                                     | XNone  |   |
| Support for attending meetings and/or travel                     | XNone  |   |
|  |  |   |
| Patents planned, issued or pending                               | XNone  |   |
| Participation on a Data  | XNone  |   |
| Safety Monitoring Board or                                       |  |   |
| Leadership or fiduciary role                                     | XNone  |   |
| in other board, society,   |  |   |
| -  |  |   |
| Stock or stock options   | XNone  |   |
|  |  |   |
| Receipt of equipment,  | XNone  |   |
| materials, drugs, medical  |  |   |
| services   |  |   |
| Other financial or non-  | XNone  |   |
| tinancial interests  |  |   |
|  | lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational eventsPayment for expert<br>testimonySupport for attending<br>meetings and/or travelPatents planned, issued or<br>pendingParticipation on a Data<br> | lectures, presentations, speakers bureaus, manuscript writing or educational events |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | 2022/11/30                  |   |
|-------------------------|-----------------------------|---|
| Your Name:              | Xixian Ke                   |   |
| Manuscript <sup>-</sup> | Title:_Diagnosis and treatn | nent of pericardial mesothelioma by mediastinal mass resection : A case |
| report                  |                             |   |
| Manuscript              | number (if known):          |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| Payment or honoraria for lectures, presentations,                | XNone  |   |
|--|--|---|
| speakers bureaus,<br>manuscript writing or<br>educational events |  |   |
| Payment for expert testimony                                     | XNone  |   |
| Support for attending meetings and/or travel                     | XNone  |   |
|  |  |   |
| Patents planned, issued or pending                               | XNone  |   |
| Participation on a Data  | XNone  |   |
| Safety Monitoring Board or                                       |  |   |
| Leadership or fiduciary role                                     | XNone  |   |
| in other board, society,   |  |   |
| -  |  |   |
| Stock or stock options   | XNone  |   |
|  |  |   |
| Receipt of equipment,  | XNone  |   |
| materials, drugs, medical  |  |   |
| services   |  |   |
| Other financial or non-  | XNone  |   |
| tinancial interests  |  |   |
|  | lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational eventsPayment for expert<br>testimonySupport for attending<br>meetings and/or travelPatents planned, issued or<br>pendingParticipation on a Data<br> | lectures, presentations, speakers bureaus, manuscript writing or educational events |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date:            | 2022/11/30             |   |
|------------------|------------------------|---|
| Your Name:       | Yongxiang S            | )ng   |
| Manuscript Title | :_Diagnosis and treatm | ent of pericardial mesothelioma by mediastinal mass resection: A case |
| report           |                        |   |
| Manuscript num   | ber (if known):        |   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | T                             | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| Payment or honoraria for lectures, presentations,                | XNone  |   |
|--|--|---|
| speakers bureaus,<br>manuscript writing or<br>educational events |  |   |
| Payment for expert testimony                                     | XNone  |   |
| Support for attending meetings and/or travel                     | XNone  |   |
|  |  |   |
| Patents planned, issued or pending                               | XNone  |   |
| Participation on a Data  | XNone  |   |
| Safety Monitoring Board or                                       |  |   |
| Leadership or fiduciary role                                     | XNone  |   |
| in other board, society,   |  |   |
| -  |  |   |
| Stock or stock options   | XNone  |   |
|  |  |   |
| Receipt of equipment,  | XNone  |   |
| materials, drugs, medical  |  |   |
| services   |  |   |
| Other financial or non-  | XNone  |   |
| tinancial interests  |  |   |
|  | lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational eventsPayment for expert<br>testimonySupport for attending<br>meetings and/or travelPatents planned, issued or<br>pendingParticipation on a Data<br> | lectures, presentations, speakers bureaus, manuscript writing or educational events |

None

# Please place an "X" next to the following statement to indicate your agreement:

| Date:28.11.2022  |
|--|
| Your Name:Luka Brcic   |
| Manuscript Title: Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: A case report |
| Manuscript number (if known):  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |  | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed)<br>Time frame: Since the initial | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|--|---|---|
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br><b>No time limit for this item.</b> |   |   |
|   |  | Time frame: past  | 36 months   |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).   | Takeda, Roche,<br>AstraZeneca, BMS  |   |
| 3 | Royalties or licenses  | X_None  |   |
| 4 | Consulting fees  | XNone   |   |

| 5  | Payment or honoraria for<br>lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational events<br>Payment for expert<br>testimony | Invitae, Eli-Lilly,<br>AstraZeneca, Roche, MSD,<br>Merck, BMS, Pfizer,<br>Novartis, Takeda, Janssen   |  |
|----|---|---|--|
| 7  | Support for attending<br>meetings and/or travel   | Pfizer, MSD   |  |
| 8  | Patents planned, issued or<br>pending   | XNone   |  |
| 9  | Participation on a Data<br>Safety Monitoring Board or<br>Advisory Board   | Invitae, Eli-Lilly,<br>AstraZeneca, Roche, MSD,<br>Merck, BMS, Pfizer,<br>Novartis, Takeda, Janssen   |  |
| 10 | Leadership or fiduciary role<br>in other board, society,<br>committee or advocacy<br>group, paid or unpaid  | Int. Secretary-Austrian<br>Society of Pathology; PPS<br>Membership and Awards<br>Committee; Member of<br>the Mesothelioma<br>Committee of IASLC |  |
| 11 | Stock or stock options  | XNone   |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical<br>writing, gifts or other<br>services   | _XNone  |  |
| 13 | Other financial or non-<br>financial interests  | XNone   |  |

The author received grants from Takeda, AstraZeneca, BMS and Roche; he also received payment for lectures and participated in advisory boards form Invitae, Eli-Lilly, AstraZeneca, Roche, MSD, Merck, BMS, Pfizer, Novartis, Takeda, Janssen; support for attending meeting from Pfizer. He is Int. Secretary-Austrian Society of Pathology; PPS Membership and Awards Committee; Member of the Mesothelioma Committee of IASLC.

#### Please place an "X" next to the following statement to indicate your agreement:

Date: 28 November 2022 Your Name: Dr. Joel W Neal Manuscript Title: Diagnosis and treatment of pericardial mesothelioma by mediastinal mass resection: A case report Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |   | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as needed)   | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|---|---|---|
|   |   | Time frame: Since the initial   | planning of the work  |
| 1 | All support for the present<br>manuscript (e.g., funding,<br>provision of study materials,<br>medical writing, article<br>processing charges, etc.)<br>No time limit for this item. | None  |   |
|   | Time frame: past 36 months  |   | 6 months  |
| 2 | Grants or contracts from<br>any entity (if not indicated<br>in item #1 above).  | Genentech/Roche<br>Merck<br>Novartis<br>Boehringer Ingelheim<br>Exelixis<br>Nektar Therapeutics<br>Takeda Phamaceuticals<br>Adaptimmune<br>GSK<br>Janssen<br>AbbVie |   |
| 3 | Royalties or licenses   | None  |   |

| 4  | Consulting fees                                 | AstraZeneca                |  |
|----|---|----------------------------|--|
|    |   | Genentech/Roche            |  |
|    |   | Exelixis                   |  |
|    |   | Jounce Therapeutics        |  |
|    |   | Takeda Pharmaceuticals     |  |
|    |   | Eli Lilly and Company      |  |
|    |   | Calithera Biosciences      |  |
|    |   | Amgen                      |  |
|    |   | Iovance Biotherapeutics    |  |
|    |   | Blueprint Pharmaceuticals  |  |
|    |   | Regeneron Pharmaceuticals  |  |
|    |   | Natera                     |  |
|    |   | Sanofi/Regeneron           |  |
|    |   | D2G Oncology               |  |
|    |   | Surface Oncology           |  |
|    |   | Turning Point Therapeutics |  |
|    |   | Mirati Therapeutics        |  |
|    |   | Gilead Sciences            |  |
|    |   | AbbVie                     |  |
| 5  | Payment or honoraria for                        | CME Matter                 |  |
|    | lectures, presentations,                        | Clinical Care Options      |  |
|    | speakers bureaus,                               | Research to Practice CME   |  |
|    | manuscript writing or                           | Medscape CME               |  |
|    | educational events                              | Biomedical Learning        |  |
|    |   | Institute CME              |  |
|    |   | MLI Peerview CME           |  |
|    |   | Prime Oncology CME         |  |
|    |   | Projects in Knowledge CME  |  |
|    |   | Rockpointe CME             |  |
|    |   | MJH Life Sciences CME      |  |
|    |   | Medical Educator           |  |
|    |   | Consortium                 |  |
| 6  |   | HMP Education              |  |
| 6  | Payment for expert                              | None                       |  |
|    | testimony                                       |                            |  |
| 7  | Current fear attanding                          | Ness                       |  |
| 7  | Support for attending<br>meetings and/or travel | None                       |  |
|    | meetings and/or travel                          |                            |  |
|    |   |                            |  |
|    |   |                            |  |
|    |   |                            |  |
| 8  | Patents planned, issued or                      | None                       |  |
|    | pending   |                            |  |
|    |   |                            |  |
| 9  | Participation on a Data                         | None                       |  |
|    | Safety Monitoring Board or                      |                            |  |
|    | Advisory Board                                  |                            |  |
| 10 | Leadership or fiduciary role                    | None                       |  |
|    | in other board, society,                        |                            |  |

|    | committee or advocacy group, paid or unpaid        |      |  |
|----|--|------|--|
| 11 | Stock or stock options                             | None |  |
|    |  |      |  |
| 12 | Receipt of equipment,<br>materials, drugs, medical | None |  |
|    | writing, gifts or other services                   |      |  |
| 13 | Other financial or non-                            | None |  |
|    | financial interests                                |      |  |
|    |  |      |  |

Dr. Neal reports grants and personal fees from Genentech/Roche, grants from Merck, grants from Novartis, grants from Boehringer Ingelheim, grants and personal fees from Exelixis, grants from Nektar Therapeutics, grants and personal fees from Takeda Pharmaceuticals, grants from Adaptimmune, grants from GSK, grants from Janssen, grants from AbbVie, grants and personal fees from AstraZeneca, personal fees from Eli Lilly and Company, personal fees from Jounce Therapeutics, personal fees from Calithera Biosciences, personal fees from Amgen, personal fees from Iovance Biotherapeutics, personal fees from Blueprint Pharmaceuticals, personal fees from D2G Oncology, personal fees from Surface Oncology, personal fees from Turning Point Therapeutics, personal fees from Gilead, other from CME Matters, other from Clinical Care Options, other from Research to Practice, other from Medscape, other from Biomedical Learning Institute, other from MJH Life Sciences, other from Medical Educator Consortium, and other from HMP Education.

### Please place an "X" next to the following statement to indicate your agreement:

| Date:                   | 2022/11/30                 |  |
|-------------------------|----------------------------|--|
| Your Name:              | Gang Xu                    |  |
| Manuscript <sup>•</sup> | Title:_Diagnosis and treat | ment of pericardial mesothelioma by mediastinal mass resection: A case |
| report                  |                            |  |
| Manuscript              | number (if known):         |  |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   |                               | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| 5  | Payment or honoraria for lectures, presentations,                | XNone  |  |
|----|--|--------|--|
|    | speakers bureaus,<br>manuscript writing or<br>educational events |        |  |
| 6  | Payment for expert testimony                                     | XNone  |  |
| 7  | Support for attending meetings and/or travel                     | XNone  |  |
|    |  |        |  |
| 8  | Patents planned, issued or pending                               | XNone  |  |
| 9  | Participation on a Data  | X None |  |
| -  | Safety Monitoring Board or                                       |        |  |
| 10 | Advisory Board<br>Leadership or fiduciary role                   | X None |  |
| 10 | in other board, society,   |        |  |
|    | committee or advocacy<br>group, paid or unpaid                   |        |  |
| 11 | Stock or stock options   | XNone  |  |
|    |  |        |  |
| 12 | Receipt of equipment,  | X None |  |
| 12 | materials, drugs, medical  |        |  |
|    | writing, gifts or other<br>services                              |        |  |
| 13 | Other financial or non-  | XNone  |  |
|    | financial interests  |        |  |
|    |  |        |  |

None

Please place an "X" next to the following statement to indicate your agreement:

| Date:              | 2022/11/30           |   |
|--------------------|----------------------|---|
| Your Name:         | Cheng Chen           |   |
| Manuscript Title:_ | Diagnosis and treatm | ent of pericardial mesothelioma by mediastinal mass resection: A case |
| report             |                      |   |
| Manuscript numb    | er (if known):       | ·   |

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

|   |                               | Name all entities with<br>whom you have this<br>relationship or indicate<br>none (add rows as<br>needed) | Specifications/Comments<br>(e.g., if payments were made to you or to your<br>institution) |
|---|-------------------------------|--|---|
|   | r                             | Time frame: Since the initial  | planning of the work  |
| 1 | All support for the present   | XNone  |   |
|   | manuscript (e.g., funding,    |  |   |
|   | provision of study materials, |  |   |
|   | medical writing, article      |  |   |
|   | processing charges, etc.)     |  |   |
|   | No time limit for this item.  |  |   |
|   |                               |  |   |
|   |                               |  |   |
|   |                               | Time frame: past   | 36 months   |
| 2 | Grants or contracts from      | XNone  |   |
|   | any entity (if not indicated  |  |   |
|   | in item #1 above).            |  |   |
| 3 | Royalties or licenses         | XNone  |   |
|   |                               |  |   |
|   |                               |  |   |
| 4 | Consulting fees               | XNone  |   |
|   |                               |  |   |

| Payment or honoraria for lectures, presentations,                | XNone  |   |
|--|--|---|
| speakers bureaus,<br>manuscript writing or<br>educational events |  |   |
| Payment for expert testimony                                     | XNone  |   |
| Support for attending meetings and/or travel                     | XNone  |   |
|  |  |   |
| Patents planned, issued or pending                               | XNone  |   |
| Participation on a Data  | XNone  |   |
| Safety Monitoring Board or                                       |  |   |
| Leadership or fiduciary role                                     | XNone  |   |
| in other board, society,   |  |   |
| -  |  |   |
| Stock or stock options   | XNone  |   |
|  |  |   |
| Receipt of equipment,  | XNone  |   |
| materials, drugs, medical  |  |   |
| services   |  |   |
| Other financial or non-  | XNone  |   |
| tinancial interests  |  |   |
|  | lectures, presentations,<br>speakers bureaus,<br>manuscript writing or<br>educational eventsPayment for expert<br>testimonySupport for attending<br>meetings and/or travelPatents planned, issued or<br>pendingParticipation on a Data<br> | lectures, presentations, speakers bureaus, manuscript writing or educational events |

None

Please place an "X" next to the following statement to indicate your agreement: